← Eichor
Study identifier: NCT05319730 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)

Condition: Esophageal Squamous Cell Carcinoma  ·  Sponsor: Merck Sharp & Dohme LLC

PhasePhase 1/Phase 2
Planned participants230
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This is a Phase 1/2, multicenter, randomized, open-label umbrella platform study to evaluate the safety and efficacy of investigational agents with or without pembrolizumab and/or chemotherapy, for the treatment of participants with second line (2L) esophageal squamous cell carcinoma (ESCC) who have previously been exposed to PD-1/PD-L1 based treatment.

This description comes directly from the study's public registry record.

Talk to the study team

Toll Free Number  ·  1-888-577-8839  ·  Trialsites@msd.com

Always discuss trial participation with your own doctor first.

Locations (59)

University of Arizona Cancer Center-University of Arizona Cancer Center ( Site 4927)Tucson, Arizona, United StatesRecruiting
UCLA Hematology/Oncology - Santa Monica ( Site 4905)Los Angeles, California, United StatesRecruiting
Hematology-Oncology Associates of Central NY, P.C. ( Site 4925)East Syracuse, New York, United StatesRecruiting
Columbia University Irving Medical Center-CUIMC Herbert Irving Comprehensive Cancer Center Clinical ( Site 4907)New York, New York, United StatesCompleted
UPMC Hillman Cancer Center-UPMC ( Site 4904)Pittsburgh, Pennsylvania, United StatesRecruiting
Liga Norte Riograndense Contra o Câncer ( Site 4303)Natal, Rio Grande do Norte, BrazilRecruiting
Hospital Nossa Senhora da Conceição ( Site 4301)Porto Alegre, Rio Grande do Sul, BrazilRecruiting
ICESP - INSTITUTO DO CÂNCER DO ESTADO DE SÃO PAULO ( Site 4300)São Paulo, BrazilRecruiting
FALP-UIDO ( Site 4400)Santiago, Region M. de Santiago, ChileRecruiting
Centro de Oncología de Precisión-Oncology ( Site 4404)Santiago, Region M. de Santiago, ChileRecruiting
Clínica las Condes ( Site 4403)Santiago, Region M. de Santiago, ChileCompleted
Clínica UC San Carlos de Apoquindo ( Site 4405)Santiago, Region M. de Santiago, ChileRecruiting

+ 47 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05319730